首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1378710

运输甲状腺素蛋白心肌病样心肌病变 (ATTR-CM) 治疗市场：按类型、按药物类型、按配销通路、按地区

Transthyretin Amyloid Cardiomyopathy Treatment Market, By Type, By Drug Type, By Distribution Channel, By Geography

出版日期: 2023年10月23日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，转甲状腺素蛋白淀粉样心肌病（ATTR-CM）治疗的全球市场规模预计为16.9亿美元，预测期内（2023-2030年）年复合成长率为31.1%。

报告范围		报告详情
基准年	2022年	2023年市场规模	16.9亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	31.10%	2030年市场规模预测	112.3亿美元

图 1. 转甲状腺素蛋白淀粉样心肌病(ATTR-CM) 治疗的全球市场占有率(%)（按类型），2023 年

运甲状腺素蛋白淀粉样心肌病（ATTR-CM）是一种罕见且严重的疾病，其特征是运甲状腺素蛋白在心臟中异常积累，可导致严重的心肌病和心臟衰竭。这些蛋白质沉积物会干扰心肌的正常功能，使其变得更僵硬，泵血效率降低。

ATTR-CM 通常是一种进行性、危及生命的疾病，主要影响老年人，但也可能出现影响年轻人的遗传形式。

ATTR-CM 的治疗是一个复杂且不断发展的领域，虽然尚无治疗方法，但有几种治疗方法旨在控制症状、减缓疾病进展并改善患者的生活品质。Masu。这些治疗方法包括旨在稳定转甲状腺素蛋白、减轻心臟衰竭症状和减少心臟淀粉样蛋白沉积负担的药物。在某些情况下，心臟移植可被视为一种治疗选择。

市场动态

全球转甲状腺素蛋白淀粉样心肌病(ATTR-CM) 治疗市场的成长是由不断探索创新治疗方法的研究推动的，包括基因静默疗法和针对疾病根本原因的新型药物，并由临床试验推动。例如，2020年总公司，美国製药公司Alexion在日本有症状的ATTR-CM受试者中评估了ALXN2060（也称为AG10）的有效性、安全性和耐受性，并已开始一项3期研究，以确定其药物动力学和耐受性。动态概况。新的市场进入预计将进一步扩大临床管线并推动全球转甲状腺素蛋白型淀粉样心肌病（ATTR-CM）治疗市场的成长。

本研究的主要特点

本报告对运输甲状腺素蛋白淀粉样心肌病（ATTR-CM）治疗市场进行了详细分析，并介绍了以 2022 年为基准年的预测期（2023-2030）的市场规模和年复合成长率。
它还阐明了各个细分市场的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
根据公司亮点、产品系列、主要亮点、业绩和策略等参数，对转甲状腺素蛋白型淀粉样心肌病(ATTR-CM) 治疗市场的主要企业进行了分析。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
全球转甲状腺素蛋白淀粉样心肌病(ATTR-CM) 治疗市场报告面向该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进入者和财务分析师。我是。
透过用于分析全球转甲状腺素蛋白淀粉样心肌病（ATTR-CM）治疗市场的各种策略矩阵，将有助于相关人员做出决策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 1.69 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	31.10%	2030 Value Projection:	US$ 11.23 Bn

Transthyretin amyloid ardiomyopathy (ATTR-CM) is a rare and serious medical condition characterized by the abnormal accumulation of transthyretin protein deposits in the heart that can lead to severe cardiomyopathy and heart failure. These protein deposits disrupt the normal functioning of the heart muscle, and causes it to become stiff and less effective in pumping blood. ATTR-CM is often a progressive and life-threatening disease that primarily affects older adults, but it can also manifest in a hereditary form that affects individuals at a younger age.

The treatment of ATTR-CM is a complex and evolving field. While there is no cure for the condition, several therapeutic approaches aim to manage symptoms, slow the progression of the disease, and improve the patient's quality of life. These treatment options can include medications designed to stabilize transthyretin proteins, alleviate heart failure symptoms, and reduce the burden of amyloid deposits in the heart. In some cases, heart transplantation may be considered as a treatment option.

Market Dynamics

Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth is driven by ongoing research and clinical trials that are exploring innovative treatments including gene-silencing therapies and novel medications that targets the underlying causes of the disease. For instance, in November 2020, Alexion, Inc., a U.S.-based pharmaceutical company, initiated a phase 3 study that evaluates the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), and to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM. With the entrance of new players in the market, the clinical pipeline is expected to expand further driving the growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Key features of the study:

This report provides an in-depth analysis of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Detailed Segmentation:

By Type:
- Hereditary Transthyretin Amyloidosis (hATTR)
- Wild Type Transthyretin Amyloidosis (wtATTR)
By Drug Type:
- Transthyretin Stabilizers
- Nonsteroidal Anti-inflammatory Drugs (NSAID)
- Rnai Therapy
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Eidos Therapeutics
- Ionis Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals
- Prothena Corporation plc
- Intellia Therapeutics, Inc.
- Corino Therapeutics, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities
- Impact Analysis
- Recent Product Approvals/Launches
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Recent Trends
- Pricing Analysis
- Key Developments
- PEST Analysis
- Porter's Analysis

4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hereditary Transthyretin Amyloidosis (hATTR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Wild Type Transthyretin Amyloidosis (wtATTR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Transthyretin Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Nonsteroidal Anti-inflammatory Drugs (NSAID)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
RNAi Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

8. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- GlaxoSmithKline Plc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Eidos Therapeutics
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Ionis Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Alnylam Pharmaceuticals
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Prothena Corporation plc
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Intellia Therapeutics, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Corino Therapeutics, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Analysts' Views

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

运输甲状腺素蛋白心肌病样心肌病变 (ATTR-CM) 治疗市场：按类型、按药物类型、按配销通路、按地区

Transthyretin Amyloid Cardiomyopathy Treatment Market, By Type, By Drug Type, By Distribution Channel, By Geography

市场动态

本研究的主要特点

目录

第1章调查目的和假设

第2章市场展望

第3章市场动态、法规及趋势分析

第4章全球转甲状腺素蛋白淀粉样心肌病（ATTR-CM）治疗市场－新型冠状病毒感染疾病（COVID-19）的影响分析

第5章全球运输甲状腺素蛋白淀粉样心肌病（ATTR-CM）治疗市场，按类型，2018-2030

第6章全球运输甲状腺素蛋白淀粉样心肌病（ATTR-CM）治疗市场，依药物类型，2018-2030

第7章全球转甲状腺素蛋白淀粉样心肌病（ATTR-CM）治疗市场，依配销通路，2018-2030

第8章全球运输甲状腺素蛋白淀粉样心肌病（ATTR-CM）治疗市场，按地区，2018-2030

第9章竞争形势

第10章章